Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
NCT00997243 · Alison Walker · PHASE2 · terminated · last registry update 2017-05-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Drug no longer being supplied by sponsor” | – | Registry record, Alison Walker |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD33 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-12-22Results posted on the registry: SWOG Cancer Research Network, arsenic trioxide + gemtuzumab ozogamicin (NCT00551460)
- 2017-06-01Results posted on the registry: Fred Hutchinson Cancer Center, gemtuzumab ozogamicin + vorinostat (NCT00673153)
- 2017-06-01Also stopped (terminated): Fred Hutchinson Cancer Center, gemtuzumab ozogamicin + vorinostat (NCT00673153)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision